Literature DB >> 29479832

Osteoporosis in chronic liver disease.

Núria Guañabens1, Albert Parés2.   

Abstract

Osteoporosis is a frequent complication in patients with chronic liver disease, especially in end-stages and in chronic cholestasis, in addition to non-alcoholic fatty liver disease, haemochromatosis and alcoholism. Mechanisms underlying osteoporosis are poorly understood, but osteoporosis mainly results from low bone formation. In this setting, sclerostin, a key regulator of the Wnt/β-catenin signalling pathway which regulates bone formation, in addition to the effects of the retained substances of cholestasis such as bilirubin and bile acids on osteoblastic cells, may influence the decreased bone formation in chronic cholestasis. Similarly, the damaging effects of iron and alcohol on osteoblastic cells may partially explain bone disease in haemochromatosis and alcoholism. A role for proinflammatory cytokines has been proposed in different conditions. Increased bone resorption may occur in cholestatic women with advanced disease. Low vitamin D, poor nutrition and hypogonadism, may be contributing factors to the full picture of bone disorders in chronic liver disease.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bisphosphonates; bone formation; bone mineral density; bone resorption; cholestasis; fractures; vitamin D

Mesh:

Substances:

Year:  2018        PMID: 29479832     DOI: 10.1111/liv.13730

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  21 in total

1.  Commonly Prescribed and Over-the-Counter Drugs as Secondary Causes of Osteoporosis-Part One.

Authors:  Joseph Pizzorno; Lara Pizzorno
Journal:  Integr Med (Encinitas)       Date:  2021-04

2.  High Prevalence of Hormonal Changes and Hepatic Osteodystrophy in Frail Patients with Cirrhosis-An Observational Study.

Authors:  Surender Singh; Sunil Taneja; Puneeta Tandon; Arka De; Nipun Verma; Madhumita Premkumar; Ajay Duseja; Radha Krishan Dhiman; Virendra Singh
Journal:  J Clin Exp Hepatol       Date:  2021-11-26

3.  Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents.

Authors:  Ruijie Xie; Ya Zhang; Tao Yan; Xiongjie Huang; Songlin Xie; Changxiong Liu; Mingjiang Liu
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

4.  Association of serum osteoprotegerin with severity of chronic liver disease in female patients: A potential biomarker.

Authors:  Saba Tariq; Sundus Tariq; Shaista Hussain; Mukhtiar Baig
Journal:  Pak J Med Sci       Date:  2020 Sep-Oct       Impact factor: 1.088

5.  Gamma-glutamyl-transferase is associated with incident hip fractures in women and men ≥ 50 years: a large population-based cohort study.

Authors:  W Brozek; H Ulmer; A Pompella; G Nagel; A Leiherer; O Preyer; H Concin; E Zitt
Journal:  Osteoporos Int       Date:  2022-01-20       Impact factor: 5.071

Review 6.  Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents with obesity: a meta-analysis.

Authors:  Yue Sun; Weiran Dai; Yuzhen Liang; Pijian Yang; Qiong Yang; Min Liang; Ning Xia
Journal:  Diabetes Metab Syndr Obes       Date:  2019-01-30       Impact factor: 3.168

Review 7.  Bone Diseases in Patients with Chronic Liver Disease.

Authors:  Hae Min Jeong; Dong Joon Kim
Journal:  Int J Mol Sci       Date:  2019-08-31       Impact factor: 5.923

8.  Comparative assessment of sarcopenia using the JSH, AWGS, and EWGSOP2 criteria and the relationship between sarcopenia, osteoporosis, and osteosarcopenia in patients with liver cirrhosis.

Authors:  Chisato Saeki; Keiko Takano; Tsunekazu Oikawa; Yuma Aoki; Tomoya Kanai; Kazuki Takakura; Masanori Nakano; Yuichi Torisu; Nobuyuki Sasaki; Masahiro Abo; Tomokazu Matsuura; Akihito Tsubota; Masayuki Saruta
Journal:  BMC Musculoskelet Disord       Date:  2019-12-26       Impact factor: 2.362

Review 9.  Influence of Iron on Bone Homeostasis.

Authors:  Enikő Balogh; György Paragh; Viktória Jeney
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-18

Review 10.  NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome.

Authors:  Valerio Rosato; Mario Masarone; Marcello Dallio; Alessandro Federico; Andrea Aglitti; Marcello Persico
Journal:  Int J Environ Res Public Health       Date:  2019-09-14       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.